Indirect Ubiquitination: Noncovalent Ubiquitin Tethering Independent of Endogenous Ubiquitination Machinery for Targeted Protein Degradation

17 April 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Heterobifunctional degrader molecules that hijack endogenous E3 ubiquitin ligases have attracted attention for the rapid and irreversible knock-down of target proteins via ubiquitination. However, the formation of appropriately oriented E3 ligase–target complexes is required for efficient ubiquitination of the target, which complicates the molecular optimization and leads to acquired drug resistance caused by the loss of E3 ligase activity and mutations at the E3–target interfaces. Here, we report on indirect ubiquitination as a chemical strategy for ubiquitination of the target substrate independent of endogenous ubiquitination machinery. Comprising a ligand molecule and a ubiquitin moiety, the designed chimeric molecule enables the non-covalent ubiquitination of target proteins, which lead to the proteasomal degradation of recombinant and endogenous proteins. Indirect ubiquitination offers a design platform for tethering of proteolytic ubiquitin-based modifiers independent of endogenous ubiquitination enzymes and expands the scope of targeted protein degradation that has been limited by the complexity and impairment of the activity of the endogenous ubiquitination machinery.

Keywords

Ubiquitin
chimera
indirect ubiquitination

Supplementary materials

Title
Description
Actions
Title
Indirect Ubiquitination: Noncovalent Ubiquitin Tethering Independent of Endogenous Ubiquitination Machinery for Targeted Protein Degradation
Description
Supporting Information
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.